Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.33 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15533764 | 0.91 | CYP2D6 (0.35) | CYP2D6SLC6A2SLC6A4SLC6A3TSHR | |
| SCHEMBL14859910 | 0.87 | CYP2D6 (0.36) | CYP2D6SLC6A2SLC6A4SLC6A3TSHR | |
| SCHEMBL24188777 | 0.87 | — | — | |
| SCHEMBL14102785 | 0.86 | — | — | |
| SCHEMBL2279102 | 0.85 | — | — | |
| SCHEMBL15830657 | 0.83 | CYP2D6 (0.32) | CYP2D6SLC6A2SLC6A4SLC6A3TSHR | |
| SCHEMBL21619902 | 0.83 | TSHR (0.31) | TSHR | |
| SCHEMBL15533757 | 0.80 | CYP2D6 (0.30) | CYP2D6SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL16848052 | 0.80 | — | — | |
| SCHEMBL19262351 | 0.79 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240359168-A1 | Mesoporous Catalyst Compounds and Uses Thereof | EXXONMOBIL RESEARCH AND ENGINEERING COMPANY | 2024-10-31 | — | — | US | disclosed |
| US-12064752-B2 | Mesoporous catalyst compounds and uses thereof | ExxonMobil Technology and Engineering Company (US) | 2024-08-20 | — | — | US | disclosed |
| US-20220143586-A1 | Mesoporous Catalyst Compounds and Uses Thereof | EXXONMOBIL RES & ENG CO (US) | 2022-05-12 | — | — | US | disclosed |
| EP-3941621-A1 | MESOPOROUS CATALYST COMPOUNDS AND USES THEREOF | ExxonMobil Research and Engineering Company (US) | 2022-01-26 | — | — | EP | disclosed |
| WO-2020190367-A1 | MESOPOROUS CATALYST COMPOUNDS AND USES THEREOF | EXXONMOBIL RESEARCH AND ENGINEERING COMPANY (US) | 2020-09-24 | — | — | WO | disclosed |
| WO-2018093694-A1 | DIAMINO-ALKYLAMINO-LINKED ARYLSULFONAMIDE COMPOUNDS WITH SELECTIVE ACTIVITY IN VOLTAGE-GATED SODIUM CHANNELS | MERCK SHARP & DOHME CORP. (US) | 2018-05-24 | — | — | WO | disclosed |
| EP-2920113-B1 | SYNTHESIS OF MCM-68 MOLECULAR SIEVE | EXXONMOBIL RES & ENG CO (US) | 2018-01-03 | — | — | EP | disclosed |
| US-9504995-B2 | Synthesis of MSE-framework type molecular sieves | EXXONMOBIL RESEARCH AND ENGINEERING COMPANY (US) | 2016-11-29 | — | — | US | disclosed |
| US-20160009723-A1 | COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2016-01-14 | — | — | US | disclosed |
| EP-2920113-A1 | SYNTHESIS OF MSE-FRAMEWORK TYPE MOLECULAR SIEVES | ExxonMobil Research and Engineering Company (US) | 2015-09-23 | — | — | EP | disclosed |
| CN-104781191-A | Synthesis of Mse-framework type molecular sieves | EXXONMOBIL RES & ENG CO | 2015-07-15 | — | — | CN | disclosed |
| US-8900548-B2 | Synthesis of MSE-framework type molecular sieves | EXXONMOBIL RESEARCH AND ENGINEERING COMPANY (US) | 2014-12-02 | — | — | US | disclosed |
| US-20140288347-A1 | COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-09-25 | — | — | US | disclosed |
| EP-2766118-A1 | SYNTHESIS OF MSE-FRAMEWORK TYPE MOLECULAR SIEVES | ExxonMobil Research and Engineering Company (US) | 2014-08-20 | — | — | EP | disclosed |
| WO-2014077995-A1 | SYNTHESIS OF MSE-FRAMEWORK TYPE MOLECULAR SIEVES | EXXONMOBIL RESEARCH AND ENGINEERING COMPANY (US) | 2014-05-22 | — | — | WO | disclosed |
| US-20140140921-A1 | SYNTHESIS OF MSE-FRAMEWORK TYPE MOLECULAR SIEVES | EXXONMOBIL RESEARCH AND ENGINEERING COMPANY (US) | 2014-05-22 | — | — | US | disclosed |
| US-8623869-B2 | Compounds useful as inhibitors of ATR kinase | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-01-07 | — | — | US | disclosed |
| US-20130095030-A1 | SYNTHESIS OF MSE-FRAMEWORK TYPE MOLECULAR SIEVES | EXXONMOBIL RESEARCH AND ENGINEERING COMPANY (US) | 2013-04-18 | — | — | US | disclosed |
| WO-2013055879-A1 | SYNTHESIS OF MSE-FRAMEWORK TYPE MOLECULAR SIEVES | EXXONMOBIL RESEARCH AND ENGINEERING COMPANY (US) | 2013-04-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140288347-A1 | COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE | ATR, CHEK1, MAP3K5 | CYP2D6 4043/4885SLC6A2 4729/4885SLC6A4 4766/4885 |
| US-20160009723-A1 | COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE | ATR, CHEK1, MAP3K5 | CYP2D6 4043/4885SLC6A2 4729/4885SLC6A4 4766/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.